CIPLA.NS Profit & Loss
Cipla Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 9 years on file
(FY2017-18 to FY2025-26)
· fetched 2026-08-23 21:42
| Line item | FY2017-18 | FY2018-19 | FY2019-20 | FY2020-21 | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹152.19 Bn | ₹163.62 Bn | ₹171.32 Bn | ₹191.60 Bn | ₹217.63 Bn | ₹227.53 Bn | ₹257.74 Bn | ₹275.48 Bn | ₹281.63 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | ₹152.19 Bn | ₹163.62 Bn | ₹171.32 Bn | ₹191.60 Bn | ₹217.63 Bn | ₹227.53 Bn | ₹257.74 Bn | ₹275.48 Bn | N/A | SegmentRevenueFromOperations |
| Other Income | ₹3.58 Bn | ₹4.77 Bn | ₹3.44 Bn | ₹2.66 Bn | ₹2.81 Bn | ₹4.75 Bn | ₹7.47 Bn | ₹8.62 Bn | ₹8.82 Bn | OtherIncome |
| Total Income | ₹155.77 Bn | ₹168.39 Bn | ₹174.76 Bn | ₹194.26 Bn | ₹220.44 Bn | ₹232.29 Bn | ₹265.21 Bn | ₹284.09 Bn | ₹290.45 Bn | Income |
| Cost of Materials Consumed | ₹44.97 Bn | ₹42.85 Bn | ₹43.77 Bn | ₹48.86 Bn | ₹55.33 Bn | ₹55.20 Bn | ₹52.21 Bn | ₹54.10 Bn | ₹58.42 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹11.74 Bn | ₹14.52 Bn | ₹18.59 Bn | ₹26.58 Bn | ₹36.87 Bn | ₹28.29 Bn | ₹35.36 Bn | ₹38.51 Bn | ₹44.51 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-2.33 Bn | ₹0.47 Bn | ₹-2.45 Bn | ₹-1.93 Bn | ₹-7.25 Bn | ₹-0.96 Bn | ₹0.63 Bn | ₹-3.32 Bn | ₹-7.44 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹26.90 Bn | ₹28.57 Bn | ₹30.27 Bn | ₹32.52 Bn | ₹35.30 Bn | ₹38.30 Bn | ₹43.10 Bn | ₹48.33 Bn | ₹53.66 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹1.14 Bn | ₹1.68 Bn | ₹1.97 Bn | ₹1.61 Bn | ₹1.06 Bn | ₹1.10 Bn | ₹0.90 Bn | ₹0.62 Bn | ₹0.54 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹13.23 Bn | ₹13.26 Bn | ₹11.75 Bn | ₹10.68 Bn | ₹10.52 Bn | ₹11.72 Bn | ₹10.51 Bn | ₹11.07 Bn | ₹12.11 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹42.64 Bn | ₹46.24 Bn | ₹49.08 Bn | ₹43.03 Bn | ₹51.85 Bn | ₹56.44 Bn | ₹63.53 Bn | ₹66.58 Bn | ₹73.64 Bn | OtherExpenses |
| Total Expenses | ₹138.30 Bn | ₹147.60 Bn | ₹152.98 Bn | ₹161.36 Bn | ₹183.69 Bn | ₹190.08 Bn | ₹206.24 Bn | ₹215.89 Bn | ₹235.45 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹17.47 Bn | ₹20.79 Bn | ₹21.78 Bn | ₹32.90 Bn | ₹36.75 Bn | ₹42.21 Bn | ₹58.97 Bn | ₹68.21 Bn | ₹55.00 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-0.78 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹-1.82 Bn | ₹-1.82 Bn | ₹-1.95 Bn | ₹0.00 Bn | ₹-2.76 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹16.69 Bn | ₹20.79 Bn | ₹21.78 Bn | ₹32.90 Bn | ₹34.93 Bn | ₹40.38 Bn | ₹57.02 Bn | ₹68.21 Bn | ₹52.24 Bn | ProfitBeforeTax |
| Tax Expense | ₹2.50 Bn | ₹5.70 Bn | ₹6.31 Bn | ₹8.89 Bn | ₹9.34 Bn | ₹12.03 Bn | ₹15.47 Bn | ₹15.30 Bn | ₹13.54 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹14.17 Bn | ₹14.92 Bn | ₹15.00 Bn | ₹23.89 Bn | ₹25.47 Bn | ₹28.33 Bn | ₹41.54 Bn | ₹52.69 Bn | ₹38.62 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹14.11 Bn | ₹15.28 Bn | ₹15.47 Bn | ₹24.05 Bn | ₹25.17 Bn | ₹28.02 Bn | ₹41.22 Bn | ₹52.73 Bn | ₹38.79 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹17.53 | ₹18.97 | ₹19.19 | ₹29.82 | ₹31.20 | ₹34.72 | ₹51.05 | ₹65.29 | ₹48.03 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹17.50 | ₹18.93 | ₹19.16 | ₹29.79 | ₹31.17 | ₹34.69 | ₹51.01 | ₹65.24 | ₹48.00 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from CIPLA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).